WO2014127772A1 - Orales kontrastmittel für die diagnostik des gastrointestinaltraktes mittels mpi - Google Patents
Orales kontrastmittel für die diagnostik des gastrointestinaltraktes mittels mpi Download PDFInfo
- Publication number
- WO2014127772A1 WO2014127772A1 PCT/DE2014/100064 DE2014100064W WO2014127772A1 WO 2014127772 A1 WO2014127772 A1 WO 2014127772A1 DE 2014100064 W DE2014100064 W DE 2014100064W WO 2014127772 A1 WO2014127772 A1 WO 2014127772A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- mpi
- diseases
- container
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1887—Agglomerates, clusters, i.e. more than one (super)(para)magnetic microparticle or nanoparticle are aggregated or entrapped in the same maxtrix
Definitions
- the invention relates to a pharmaceutically acceptable colloidal suspension containing a
- the invention further relates to the use of this pharmaceutically acceptable colloidal suspension as an oral contrast agent for the diagnosis of the gastrointestinal tract and the use of the contrast agent for the diagnosis of proliferative diseases, inflammatory and
- the MPI magnetic particle imaging
- the MPI magnetic particle imaging
- a contrast agent is available, with which a quantitative imaging in vivo is possible.
- high contrast angiographic imaging succeeds because MPI does not detect an anatomical background signal.
- the sensitivity of the method allows 3D real-time imaging with clinically approved doses of iron oxide nanoparticles in small animals.
- MPI promises advantages over the existing noninvasive modalities of CT and MRI (1).
- oral administration of the iron oxide nanoparticles as part of an oral contrast medium suspension the contents of the intestine can be labeled.
- the lack of anatomical background signal can be achieved with complete lining of the intestine an optimal contrast to the intestinal wall and produce a 3D "impression" in which, for example, polyps represent as "invaginations".
- galenics are of particular importance at MPI - on the one hand (as in colonography) the stool must have a relatively uniform concentration of contrast medium, in addition it must be ensured that it lines the intestine well.
- This method is similar to fecal tagging, which has been successfully used to enhance contrast in CT and MRI colonoscopy (4, 6) MPI allows the imaging of the whole intestinal volume, the uptake being accomplished by sequential real-time measurement of intestinal tracts, for the detection of polyps as the complete In the early stages of colorectal cancer, a software algorithm can then be used, similar to the software that is available for CT-based early diagnosis (CT colonography).
- the MPI method Compared to CT colonography, the MPI method has the advantage that no harmful radiation is used. On the one hand, this could increase the acceptance of colonography as a screening method. On the other hand, with MPI measurements over a period of a few minutes would be possible, which would allow the representation of the peristaltic movements. This additional dynamic information would facilitate the localization of air bubbles and the identification of temporarily collapsed intestinal areas. In CT colonography, this information is obtained by comparing two images of the patient, one supine and one prone. With the help of the additionally obtained dynamic information, disadvantages due to the lack of colon cleansing in the planned MPI procedure could be compensated. In addition, the expectation is that the combination of high contrast and dynamic information in the MPI procedure will eliminate both the colon cleansing and the expansion of the colon with air or CO2.
- the main advantage of the MPI method is the possibility of faster imaging, which should lead to cost advantages through short examination times.
- MRI must slow down peristalsis by administering buscopan to avoid imaging motion artifacts.
- the high time resolution of the MPI method would allow real-time 3D imaging and thus, as already described in the previous paragraph, to provide additional dynamic information while shortening the total examination time. Also, the dilation of the colon with gas or liquid required in MRI colonography could be eliminated.
- MPI-based colorectal cancer screening is expected to result in improved compliance. Preventing colon cancer is found at a stage where it is still completely curable. In the late stages, when symptoms guide the patient to the doctor, the chances of survival are much lower, and low compliance will result in major health system costs.
- the object of the invention was therefore to provide a contrast agent for oral administration, which can be used for diagnostic issues in Gastro intesti na I Tha by means of MPI.
- an oral contrast agent can be provided for the diagnosis of the gastrointestinal tract, this contrast agent being a
- pharmaceutically acceptable colloidal suspension comprising a pharmaceutically acceptable enveloped container designed as a "double container” having a diameter of 0.6-300 ⁇ m and an inner container configured as a microcapsule having a colloidal solution or suspension, contained in the magnetic particles.
- the double container has a diameter of 5 - 100 ⁇ 8 ⁇ .
- the magnetic particles are incorporated in a biodegradable matrix, the nature of which
- Brownian molecular motion allows. Therefore, this matrix is characterized by a suitable viscosity.
- the viscosities measured in millipascal seconds can be between 1 and 2000.
- the viscosity can be adjusted, for example, by a glycerol-water solution, sugar-water solution, oils or polymer mixtures. The average person skilled in the art can check in the form of preliminary tests which biodegradable materials the Brownsche
- the skilled artisan does not have to be inventive, but he can easily test the biodegradable materials known in the art by routine experimentation.
- the outer and inner containers are filled with a biodegradable matrix. If the matrix has a viscosity in the range of 0.5 - 100 mPa * s (millipascal seconds), the Brownian motion of the magnetic nanoparticles is maintained.
- MPI as a new imaging method requires a contrast agent for imaging.
- various contrast agents in the form of iron oxide nanoparticle preparations are available.
- there was no suitable contrast agent until the invention came about, since the
- Gastrointestinal tract can be adapted to the specific magnetic susceptibility of the given particle.
- the agent according to the invention is surprisingly toxicologically harmless, since the lowest possible systemic absorption through the mucosa of the gastrointestinal tract is achieved by the choice of suitable diameter for the oral contrast agent. It was completely surprising that the stated requirements can be met by a wrapped container, which is designed as a "double container”. This "double container"
- the inner container represents a microcapsule, ie a hollow body that can absorb magnetic particles in colloidal solution.
- the preparation of such microparticles is well known and can be done in a variety of ways so that one of ordinary skill in the art can make them at any time.
- Known method for producing suitable microparticles are well known and can be done in a variety of ways so that one of ordinary skill in the art can make them at any time.
- Microparticles may include interfacial polymerization, phase separation and coacervation, solvent evaporation techniques, spray methods, drying methods, and
- the magnetic particles are incorporated into a biodegradable matrix so that the Brownian molecular motion of these particles is possible.
- This has the advantage that using suitable sequences, a higher signal yield is possible in the acquisition of MPI signals. Since the person skilled in the art can easily find such biodegradable materials, the technical teaching of the invention is sufficiently disclosed. Particularly good signal yields are achieved when the particles in the inner container can rotate freely and be moved so that they can align with their preferred magnetic direction corresponding to a preferred direction given by the sequence.
- the particles, in a container that allows for Brownian motion will have a more uniform magnetization behavior and thus better MPI signal behavior than those introduced into a container that prevents Brownian motion. Decisive here is that the particles in the inner container can rotate freely and be moved, so that they are with their magnetic
- Preferred direction can be aligned according to a preferred direction given by the sequence. Particles in a container that inhibit Brownian motion can not align by rotation and displacement, and therefore the preferred magnetic directions are randomly distributed. The particles in a container, the Brownsche Thus, under a suitable sequence, molecular motion permits a more uniform magnetization behavior and thus better MPI signal behavior than those introduced into a container which prevents Brownian motion.
- the microcapsules consist of a biocompatible and toxicologically harmless synthetic polymer or copolymer.
- materials of the microcapsules biocompatible, metabolically stable and slowly biodegradable natural and synthetic polymers or copolymers, eg cyanoacrylates, polylactides
- the patent to Pison et al., WO 2007093451 A2 discloses preferred materials for the microcapsule (5).
- the outer diameter of the inner container, d. H. the size of the microcapsules is preferably 0.5-50 ⁇ , preferably between 0.3 ⁇ and 10 ⁇ .
- the microcapsules have no uniform outer diameter, but it is a
- Size distribution between 0.5 and 50 ⁇ , preferably between 3 to 5 ⁇ , more preferably between 0.2 and 5 ⁇ , in the sense of a normal distribution before.
- the inner container is enveloped by an outer container.
- the outer container protects the inner container and its contents.
- the magnetic nanoparticles in the inner container which are located in a biodegradable matrix, are released only after the gastric passage, preferably in the middle (but not necessarily there, as a result of surface structuring and material selection for the outer container Release in the duodenum), whereby the containers are protected from the acidity of the stomach.
- the pharmaceutical preparations according to the invention which can play a role by conventional methods such as pressing, dipping or
- Fluid bed process or Kessel stearing are prepared and contain carriers and other conventional auxiliaries, such as starch, z.
- auxiliaries such as starch, z.
- the coating solution usually consists of sugar and / or corn syrup, and contains gelatin, gum arabic,
- Preparation of dosage forms may be any of the usual flow regulating, lubricating or
- the embodiment of the oral contrast agent as a double container, in which an inner container or a microcapsule is enveloped by another container, wherein the outer container has a diameter of 6 - 300 ⁇ , preferably between 5 - 100 ⁇ , to a particularly good M PI signal behavior. Especially with the size of the inner container between 3 - 10 ⁇ particularly good signals are obtained.
- the outer shell of the double container is enteric-coated. This ensures that the colloidal solution is stabilized, whereby the inner container is released only after the passage of the upper gastrointestinal tract.
- the inner container or the microcapsule comprises at least three magnetic single domain particles of a size between 3 nm - 20 nm, which are present in a biodegradable matrix or at least two polycrystalline, magnetic iron oxide cores with a diameter of 10 - 300 nm, which are also present in a biodegradable matrix.
- the average person skilled in the art will select the biodegradable matrix to allow Brownian motion.
- the characteristic of the biodegradable matrix permitting Brownian molecular motion is not a task faced by a person skilled in the art who can only be solved by means of inventive step; but it is a functional feature of the invention, which can implement the skilled person without inventive step.
- the oral contrast agents solve the problem of the invention particularly well if they have at least three single-domain magnetic particles with a size between 3 and 20 nm or at least two polycrystalline magnetic iron oxide cores with a diameter of 10 nm to 300 nm mentioned parameter ranges do not represent an arbitrary range, but give the size diameter again, which is a surprisingly good implementation of
- Gastrointestinal tract can be detected very well. This relates in particular to proliferative diseases, inflammatory and autoimmune diseases,
- Infectious diseases hormonal diseases and hereditary diseases.
- Particularly preferred are colorectal cancer screening.
- the biodegradable matrix is within the inner container, i. H. the microcapsule, a synthetic polymer or copolymer, a starch or a derivative thereof, a dextran or a derivative thereof, a cyclodextran or a derivative thereof, a fatty acid, a polysaccharide, a lecithin or a mono-, di- or
- Triglyceride or a derivative or a mixture thereof are those that are known in the art, it was surprising that these substances especially with regard to the oral contrast agent for diagnostic issues in the gastrointestinal tract by MPI to particularly good
- Gastrointestinal tract allow a particularly good early detection, especially of colon cancer.
- the combination of the compounds mentioned and the preferred size of the magnetic particles leads to a surprisingly good contrast, which makes it possible to diagnose even the smallest changes within the gastrointestinal tract.
- the magnetic particles comprise magnetite or maghemite or mixtures thereof or else rare earth metal ions, transition metal ions and / or alloys thereof. It was particularly surprising that the combination of the magnetic particles mentioned in connection with the claimed size of the magnetic single domain or the polycrystalline, magnetic iron oxide cores in connection with the preferred biodegradable matrix to surprisingly good results in the diagnosis of the gastrointestinal tract, especially in colon cancer , leads. Especially in the early diagnosis of diseases of the
- Gastrointestinal tract surprisingly good results can be achieved by means of MPI in connection with the oral contrast medium to be administered according to the invention. This was surprising because many individual components of the teaching according to the invention were known. However, it was not known that the combination of the known agents and parameters leads to surprisingly good results in the diagnosis of the gastrointestinal tract. It was surprising that, above all, proliferative diseases, inflammatory and others.
- Congenital diseases can be diagnosed at a surprisingly early stage.
- the iron concentration of the magnetic particles is 0.01 mmol / L to 0.1 mol / L, preferably 1 mmol / L to 100 mmol / L. Above all, the concentration of 1 mmol / L to 100 mmol / L leads to a particularly good solution of the object of the invention.
- the advantageous size of the magnetic particles (3 nm - 20 nm at magnetic
- the teaching of the invention therefore also relates to a method for the diagnosis of
- the invention also relates to a pharmaceutically acceptable colloidal suspension comprising a pharmaceutically acceptable enveloped container designed as a "double container" having a diameter of from 0.6 ⁇ m to 300 ⁇ m, preferably between 5 ⁇ m and 100 ⁇ m, and its inner container
- the invention relates to the use of said pharmaceutically acceptable colloidal suspension or oral contrast agent for the preparation of a diagnostic agent for use in magnetic particle detection imaging (MPI) for the diagnosis of a disease in the gastrointestinal tract selected from the group comprising proliferative diseases, inflammatory and autoimmune diseases,
- MPI magnetic particle detection imaging
- the proliferative disease is selected from the group comprising: a tumor, a precancerose, a dysplasia, a neuroendocrine tumor, an endometriosis and / or a metaplasia.
- the inflammatory and autoimmune disease is selected from the group comprising inflammatory
- Bowel disease Crohn's disease and / or systemic lupus erythematous.
- the infectious disease is selected from the group comprising a parasitic disease, a bacterial disease and / or a viral disease.
- the hormonal disease is selected from the group comprising a disease of the sugar metabolism, the
- the hereditary disease is selected from the group comprising an autosomal recessive, an autosomal dominant, a gonosomal and / or a mitochondrial and / or extrachromosomal Erbh or a disease that can be attributed to a genetic disposition.
- Gastrointestinal tract Here, proliferative diseases, inflammatory and others.
- Erbbrien with high security can be detected or can be diagnosed at a very early stage.
- Microcapsules with a diameter between 3 and 10 ⁇ m are loaded with magnetic particles in such a way that they have at least three magnetic single domain particles with a size between 3 and 20 nm or at least two polycrystalline, magnetic iron oxide cores with a diameter of 10 nm to 300 nm
- These microcapsules are enveloped by a container, so that the double containers have a size of 5 ⁇ to 100 ⁇ .
- the magnetic particles (at least magnetite or maghemite) had an iron concentration of 1 mmol / L to 100 mmol / L within the inner container (microcapsules).
- the biodegradable matrix of the container comprised synthetic polymers or copolymers, a starch or derivative thereof, a dextran or derivative thereof, a cyclodextran or derivative thereof, a fatty acid, a polysaccharide, a lecithin or a mono-, di- or triglyceride Derivative thereof or mixtures thereof.
- Gastrointestinal tract can be diagnosed very safely and early. Especially good
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/767,919 US20150374855A1 (en) | 2013-02-20 | 2014-02-20 | Oral contrast medium for the diagnostic investigation of the gastrointestinal tract by means of mpi |
JP2015558348A JP2016509032A (ja) | 2013-02-20 | 2014-02-20 | Mpiを用いた消化管の診断検査用経口造影剤 |
EP14712192.5A EP2958597A1 (de) | 2013-02-20 | 2014-02-20 | Orales kontrastmittel für die diagnostik des gastrointestinaltraktes mittels mpi |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102013101686 | 2013-02-20 | ||
DE102013101686.3 | 2013-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014127772A1 true WO2014127772A1 (de) | 2014-08-28 |
Family
ID=50349398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2014/100064 WO2014127772A1 (de) | 2013-02-20 | 2014-02-20 | Orales kontrastmittel für die diagnostik des gastrointestinaltraktes mittels mpi |
Country Status (4)
Country | Link |
---|---|
US (1) | US20150374855A1 (de) |
EP (1) | EP2958597A1 (de) |
JP (1) | JP2016509032A (de) |
WO (1) | WO2014127772A1 (de) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992017514A1 (en) | 1991-04-05 | 1992-10-15 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
DE10151778A1 (de) | 2001-10-19 | 2003-05-08 | Philips Corp Intellectual Pty | Verfahren zur Ermittlung der räumlichen Verteilung magnetischer Partikel |
WO2007000350A1 (en) | 2005-06-29 | 2007-01-04 | Bayer Schering Pharma Aktiengesellschaft | Compositions containing magnetic iron oxide particles, and use of said compositions in magnetic particle imaging |
WO2007093451A2 (en) | 2006-02-17 | 2007-08-23 | Topass Gmbh | Multimodal imaging using a three compartment polymer nanoparticle with cell specificity |
US20110177231A1 (en) * | 2010-01-16 | 2011-07-21 | Alexander Grinberg | Nano-, Micro-, Macro- Encapsulation And Release Of Materials |
EP2452622A1 (de) * | 2010-11-11 | 2012-05-16 | Philips Intellectual Property & Standards GmbH | Dickdarmuntersuchung mithilfe der Magnetpartikelabbildung |
WO2013019137A1 (en) * | 2011-08-04 | 2013-02-07 | Institution Of The Russian Academy Of Sciences Tomsk Scientific Center, Siberian Branch, Russian Academy Of Sciences | Oxide ferrimagnetics with spinel structure nanoparticles and iron oxide nanoparticles, biocompatible aqueous colloidal systems comprising nanoparticles, ferriliposomes, and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG175681A1 (en) * | 2006-10-25 | 2011-11-28 | Proteus Biomedical Inc | Controlled activation ingestible identifier |
DE102007004424A1 (de) * | 2007-01-23 | 2008-07-24 | Bayer Schering Pharma Aktiengesellschaft | Eisenoxid-bindende Peptide |
JP2011516462A (ja) * | 2008-04-03 | 2011-05-26 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 磁性粒子イメージング用生体適合物 |
JP5354566B2 (ja) * | 2008-07-25 | 2013-11-27 | 名糖産業株式会社 | カチオン性多糖磁性粒子複合体 |
JP5763631B2 (ja) * | 2009-07-01 | 2015-08-12 | コーニンクレッカ フィリップス エヌ ヴェ | Mpi誘導による薬物送達のための刺激応答性キャリア |
WO2011163136A2 (en) * | 2010-06-21 | 2011-12-29 | University of Washington Center for Commercialization | Tuned multifunctional magnetic nanoparticles for biomedicine |
-
2014
- 2014-02-20 US US14/767,919 patent/US20150374855A1/en not_active Abandoned
- 2014-02-20 EP EP14712192.5A patent/EP2958597A1/de not_active Withdrawn
- 2014-02-20 JP JP2015558348A patent/JP2016509032A/ja active Pending
- 2014-02-20 WO PCT/DE2014/100064 patent/WO2014127772A1/de active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992017514A1 (en) | 1991-04-05 | 1992-10-15 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
DE10151778A1 (de) | 2001-10-19 | 2003-05-08 | Philips Corp Intellectual Pty | Verfahren zur Ermittlung der räumlichen Verteilung magnetischer Partikel |
WO2007000350A1 (en) | 2005-06-29 | 2007-01-04 | Bayer Schering Pharma Aktiengesellschaft | Compositions containing magnetic iron oxide particles, and use of said compositions in magnetic particle imaging |
WO2007093451A2 (en) | 2006-02-17 | 2007-08-23 | Topass Gmbh | Multimodal imaging using a three compartment polymer nanoparticle with cell specificity |
US20110177231A1 (en) * | 2010-01-16 | 2011-07-21 | Alexander Grinberg | Nano-, Micro-, Macro- Encapsulation And Release Of Materials |
EP2452622A1 (de) * | 2010-11-11 | 2012-05-16 | Philips Intellectual Property & Standards GmbH | Dickdarmuntersuchung mithilfe der Magnetpartikelabbildung |
WO2013019137A1 (en) * | 2011-08-04 | 2013-02-07 | Institution Of The Russian Academy Of Sciences Tomsk Scientific Center, Siberian Branch, Russian Academy Of Sciences | Oxide ferrimagnetics with spinel structure nanoparticles and iron oxide nanoparticles, biocompatible aqueous colloidal systems comprising nanoparticles, ferriliposomes, and uses thereof |
Non-Patent Citations (9)
Title |
---|
ACHIAM MP; L?GAGER VB; CHABANOVA E; EEGHOLM B; THOMSEN HS; ROSENBERG J: "Diagnostic accuracy of MR colonography with fecal tagging", ABDOM IMAGING, vol. 34, 2009, pages 483 - 490, XP019738009 |
BORGERT J; GLEICH B; KUHN MH; RAHMER JE; SCHMALE: "Colon screening by using magnetic particle imaging", GOOGLE PATENTS, 2012 |
BRIEL A; GLEICH B; WEIZENECKER J; ROHRER M; WEINMANN HJ; PIETSCH H; LAWACZECK R; ROTHE M; THOMSEN J: "Compositions containing magnetic iron oxide particles, and use of said compositions in magnetic particle imaging", GOOGLE PATENTS, 2007 |
FRENTZ SM; SUMMERS RM: "Current status of CT colonography", ACADEMIC RADIOLOGY, vol. 13, 2006, pages 1517 - 1531, XP028012571, DOI: doi:10.1016/j.acra.2006.09.056 |
PISON U.: "Multimodal imaging using a three compartment polymer nanoparticle with cell specificity", GOOGLE PATENTS, 2007 |
THOMTON E; MORRIN MM; YEE J: "Current Status of MR Colonography 1", RADIOGRAPHICS, vol. 30, 2010, pages 201 - 218 |
UNGER EC.: "Low density microspheres and their use as contrast agents for computed tomography", GOOGLE PATENTS, 1992 |
WEIZENECKER J ET AL: "LETTER TO THE EDITOR; Three-dimensional real-time in vivo magnetic particle imaging", PHYSICS IN MEDICINE AND BIOLOGY, INSTITUTE OF PHYSICS PUBLISHING, BRISTOL GB, vol. 54, no. 5, 7 March 2009 (2009-03-07), pages L1 - L10, XP020149861, ISSN: 0031-9155, DOI: 10.1088/0031-9155/54/5/L01 * |
WEIZENECKER J: "Three-dimensional real-time. in vivo magnetic particle imaging", PHYSICS IN MEDICINE AND BIOLOGY, vol. 54, 2009, pages L1 - L10, XP002611968, DOI: doi:10.1088/0031-9155/54/5/L01 |
Also Published As
Publication number | Publication date |
---|---|
JP2016509032A (ja) | 2016-03-24 |
EP2958597A1 (de) | 2015-12-30 |
US20150374855A1 (en) | 2015-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wallyn et al. | Biomedical imaging: principles, technologies, clinical aspects, contrast agents, limitations and future trends in nanomedicines | |
Cormode et al. | Nanoparticle contrast agents for computed tomography: a focus on micelles | |
JP2865172B2 (ja) | 経皮のリンパ管造影 | |
CN105142681B (zh) | 含半氟碳化合物的造影剂 | |
DE69920425T2 (de) | Verwendung von teilchenförmigen kontrastmitteln in der diagnostischen bilderzeugung zur untersuchung physiologischer parameter | |
DE102005059751A1 (de) | Wässrige Dispersion von superparamagnetischen Eindomänenteilchen, deren Herstellung und Verwendung zur Diagnose und Therapie | |
Wang et al. | BaHoF5 nanoprobes as high-performance contrast agents for multi-modal CT imaging of ischemic stroke | |
CN101951835A (zh) | 纳米级对比剂和使用方法 | |
CN104144708A (zh) | 基于脂质的纳米粒子 | |
JP2005519657A (ja) | ナノ微粒子造影剤を用いた血管撮像の方法 | |
Li et al. | Spectral computed tomography with inorganic nanomaterials: State-of-the-art | |
WO2009000785A2 (de) | Positronen emittierende anorganische partikel enthaltende zusammensetzungen und deren verwendung in der medizin, insbesondere für diagnostische verfahren | |
EP2005970A1 (de) | Bildgebende Diagnostik durch Kombination von Kontrastmitteln | |
Wang et al. | Gadolinium-loaded solid lipid nanoparticles for colorectal tumor in MR colonography | |
AU2002365395B2 (en) | Formulations for use in medical or diagnostic procedures | |
DE102023125435A1 (de) | Zweikomponenten-Hilfswicklungsmittel für die Magensonographie und Herstellungsverfahren davon | |
JP2009023929A (ja) | 微小循環構築の血管種別選択的造影剤および造影方法 | |
WO2020198534A1 (en) | Imaging agents and methods of using the same | |
WO2014127772A1 (de) | Orales kontrastmittel für die diagnostik des gastrointestinaltraktes mittels mpi | |
Kirchhoff et al. | Combined two-photon laser-scanning microscopy and spectral microCT X-ray imaging to characterize the cellular signature and evolution of microstroke foci | |
DE60026743T2 (de) | Verwendung von Kontrastmitteln zur Herstellung eines Diagnostischen Mittels für die Darmlumenbildgebung | |
CN105592862A (zh) | 肝脏预饱和及其后造影剂的施用 | |
DE102005028882A1 (de) | Lösung und Verfahren zum Unterstützen der Bildgebung an einem Patienten | |
US20230284994A1 (en) | Pet-ct imaging methods, contrast agents and pharmaceutical compositions for use in said imaging methods | |
WO2002022011A1 (de) | Verfahren zur bildlichen darstellung und diagnose von thromben mittels kernspintomographie unter verwendung partikulärer kontrastmittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14712192 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014712192 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14767919 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2015558348 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1120140009172 Country of ref document: DE |